- Home
- SJT vs SCPH Comparison
SJT vs SCPH Comparison
Compare SJT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- SCPH
- Stock Information
- Founded
- SJT 1980
- SCPH 2013
- Country
- SJT United States
- SCPH United States
- Employees
- SJT N/A
- SCPH N/A
- Industry
- SJT Oil & Gas Production
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- SCPH Health Care
- Exchange
- SJT Nasdaq
- SCPH Nasdaq
- Market Cap
- SJT 269.4M
- SCPH 299.0M
- IPO Year
- SJT N/A
- SCPH 2017
- Fundamental
- Price
- SJT $5.78
- SCPH $5.63
- Analyst Decision
- SJT
- SCPH Buy
- Analyst Count
- SJT 0
- SCPH 3
- Target Price
- SJT N/A
- SCPH $12.00
- AVG Volume (30 Days)
- SJT 200.0K
- SCPH 2.3M
- Earning Date
- SJT 11-13-2025
- SCPH 11-12-2025
- Dividend Yield
- SJT N/A
- SCPH N/A
- EPS Growth
- SJT N/A
- SCPH N/A
- EPS
- SJT N/A
- SCPH N/A
- Revenue
- SJT $42,635.00
- SCPH $49,969,000.00
- Revenue This Year
- SJT N/A
- SCPH $108.95
- Revenue Next Year
- SJT N/A
- SCPH $78.30
- P/E Ratio
- SJT N/A
- SCPH N/A
- Revenue Growth
- SJT N/A
- SCPH 107.79
- 52 Week Low
- SJT $3.27
- SCPH $1.94
- 52 Week High
- SJT $7.22
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- SJT 47.52
- SCPH 64.37
- Support Level
- SJT $5.73
- SCPH $4.33
- Resistance Level
- SJT $5.91
- SCPH $5.62
- Average True Range (ATR)
- SJT 0.13
- SCPH 0.05
- MACD
- SJT 0.01
- SCPH 0.01
- Stochastic Oscillator
- SJT 26.47
- SCPH 93.75
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.